Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
302 questions in 48 reviews · Neuromuscular
current versionsNo studies 302 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
A sensor‐based, interactive exercise programme vs no sensor‐based, interactive exercise programme Adverse events/serious adverse events · people with NMD Interventions for promoting physical activity in people with neuromuscular disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Idebenone vs placebo Hospitalisation due to respiratory infection · people with Duchenne muscular dystrophy and progressive respiratory decline Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive… (2021) · Cochrane | no estimate extracted | NR | No studies |
Oral hydroxyurea vs placebo Acquiring the ability to stand or walk · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral hydroxyurea vs placebo Change in quality of life · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Change in muscle strength · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Change in quality of life · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Change in pulmonary function · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intrathecal injected nusinersen vs sham procedure Time from beginning of treatment until death or full‐time ventilation · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral creatine vs placebo Acquiring the ability to stand or walk · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral olesoxime vs placebo Change in muscle strength · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral olesoxime vs placebo Acquiring the ability to stand or walk · non‐ambulatory children and adolescents with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral phenylbutyrate vs placebo Acquiring the ability to stand or walk · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral phenylbutyrate vs placebo Change in quality of life · children with SMA type II Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous somatotropin vs placebo Acquiring the ability to stand or walk · children and adults with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravenous thyrotropin releasing hormone vs placebo Change in disability score · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravenous thyrotropin releasing hormone vs placebo Acquiring the ability to stand or walk · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravenous thyrotropin releasing hormone vs placebo Change in quality of life · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intravenous thyrotropin releasing hormone vs placebo Change in pulmonary function · children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral valproic acid plus acetyl‐L‐carnitine vs placebo Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral valproic acid vs placebo Acquiring the ability to stand or walk · ambulatory adults with SMA type III Drug treatment for spinal muscular atrophy types II and III (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Function · participants with relapsed or recurrent CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Foot alignment · participants with relapsed or recurrent CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gait assessment · participants with relapsed or recurrent CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with relapsed or recurrent CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · participants with relapsed or recurrent CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Function · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Foot alignment · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gait assessment · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · participants with neglected CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Function ‐ · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gait assessment · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified) Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gait assessment · participants with CTEV at initial presentation Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Function · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Gait assessment · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with resistant CTEV Interventions for congenital talipes equinovarus (clubfoot) (2020) · Cochrane | no estimate extracted | NR | No studies |
Cerebrospinal fluid filtration vs plasma exchange Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Cerebrospinal fluid filtration vs plasma exchange Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Improvement in disability grade after 4 weeks Scale ranges from grade 0 to 6 where 0 is healthy and 6 is dead · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Time from randomisation until recovery of unaided walking · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Tripterygium polyglycoside vs corticosteroids Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Time from randomisation until discontinuation of ventilation (for those ventilated) · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Death or disability after 12 months · people with Guillain‐Barré syndrome Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cramp intensity (moderate or worse at 4 weeks) · pregnant women with leg cramps Magnesium for skeletal muscle cramps (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cramp duration (≥ 1 minute at 4 weeks) · pregnant women with leg cramps Magnesium for skeletal muscle cramps (2020) · Cochrane | no estimate extracted | NR | No studies |
Tafamidis vs placebo Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP Pharmacological treatment for familial amyloid polyneuropathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Inotersen vs placebo Disability due to FAP progression Not measured · people with TTR‐FAP Pharmacological treatment for familial amyloid polyneuropathy (2020) · Cochrane | no estimate extracted | NR | No studies |
Strength training vs no training Time‐scored functional assessments of muscle performance · people with facioscapulohumeral muscular dystrophy Strength training and aerobic exercise training for muscle disease (2019) · Cochrane | no estimate extracted | NR | No studies |